Navigation Links
Many Breakthrough Drugs Come From Publicly Funded Research: Study
Date:2/9/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Feb. 9 (HealthDay News) -- A surprising number of valuable new drugs and vaccines approved in the United States have arisen wholly from research funded by the public sector, new research finds.

The authors of a study published Feb. 10 in the New England Journal of Medicine count 153 new drugs and vaccines from public sector research institutes over the past 40 years. They include Remicade (infliximab), considered a giant step forward in the treatment of rheumatoid arthritis and other inflammatory and autoimmune disorders, and Lyrica (pregabalin), used to treat pain neuropathy, fibromyalgia and pain from shingles.

"Not only do federal funding programs, such as those from the National Institutes of Health and the National Science Foundation, advance the scientific knowledge base of the country, but they contribute practical advances that can help people and create economic opportunity," said study author Ashley J. Stevens, a lecturer at the Boston University School of Medicine and senior research associate at the university's Institute of Technology Entrepreneurship and Commercialization.

Traditionally, publicly funded researchers tended to dig up the causes and vulnerabilities of a particular disease while the sexier follow-up of actual drug development was left to pharmaceutical companies.

That apparently has changed, according to the study team, which included researchers from Norway and from the Office of Technology Transfer at the U.S. National Institutes of Health (NIH).

Thanks to legislation passed in 1980, universities, teaching hospitals, nonprofit research institutes and federal laboratories could start owning and licensing intellectual property coming from federally funded research, the authors stated.

This coincided with the boom in biotechnology research, which made so many new biologic drugs possible.

The 153 new entities identified by the authors included 93 small-molecule drugs, 36 biological agents, 15 vaccines, eight diagnostic tools and one over-the-counter drug. More than half were to treat or prevent cancer or infectious diseases. And many were fast-tracked to approval, suggesting that their effect was considered substantial. The therapeutic effect of these public sector-developed drugs will likely be disproportionately large, the researchers said.

The news comes in the midst of looming concerns about budget cuts and the future of government-funded research.

"This study helps justify sustained federal support for the NIH," said Jon Retzlaff, managing director of science policy and government affairs at the American Association for Cancer Research (AACR) in Washington, D.C.

"The AACR is extremely concerned about the current funding environment, and specifically the threats of budget cuts to the NIH and the National Cancer Institute. It is imperative that at this critical juncture Congress not waver in its longstanding commitment to providing the resources and support for research and discovery efforts," he said.

"These are what fuel advances in cancer prevention, diagnosis, care and treatment," he added.

"Long-term flat funding or, worse, a reduction in funds for biomedical research and cancer research will slow research progress and squander invaluable scientific opportunities to the detriment of our nation's health, our fragile economy and our global competitiveness," Retzlaff said.

As legislators try to balance the federal budget, these funds must not be considered discretionary, he added. "This data shows that these are part of our economic development," he said.

More information

The U.S. Food and Drug Administration has more on how drugs are developed and approved.

SOURCE: Ashley J. Stevens, D.Phil, lecturer, Boston University School of Medicine, and senior research associate, BU Institute of Technology Entrepreneurship and Commercialization; Jon Retzlaff, managing director, science policy and government affairs, American Association for Cancer Research; Feb. 10, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Breakthrough for more efficient drug development
2. Mount Sinai researchers make major breakthrough in melanoma research
3. Autism breakthrough: Researchers identify possible treatment for impaired sociability
4. Breakthrough in cancer vaccine research
5. Breakthrough in understanding life-threatening childhood liver disease
6. Popular Mechanics breakthrough awardees announced
7. University of East Anglia makes cancer breakthrough
8. European Nurse Society calls to action on breakthrough cancer pain
9. Better cholesterol drugs may follow Saint Louis University researchers breakthrough
10. Breakthrough in drug trial offers hope for heart attack patients
11. Novel nanotechnology collaboration leads to breakthrough in cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Breakthrough Drugs Come From Publicly Funded Research: Study
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme ... on Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over ... The 5k Run and Walk and 1-mile walk were held to increase awareness ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
(Date:4/27/2016)... NEW DELHI , April 27, 2016 ... CSR initiative to save newborns ... ,s hospital for women & newborns in collaboration with Breast ... has launched the first Pasteurized Human Milk Bank, ,Amaara, in ... the best nutritional food source for infants and should be ...
Breaking Medicine Technology: